Indivumed, a biotechnology company focused on precision oncology, has announced its expansion of partnership with the world-renowned Wilmot Cancer Institute at the University of Rochester Medical ...
TPAG hails introduction of the National Blood Transfusion Bills in Parliament as it saves scores of patients: Our Bureau, Bengaluru Friday, December 12, 2025, 15:10 Hrs [IST] Thal ...
Statement of the WHO Global Advisory Committee on Vaccine Safety on vaccines and autism: Geneva Friday, December 12, 2025, 15:00 Hrs [IST] On 27 November 2025, the WHO Global Advi ...
Lupin Manufacturing Solutions and PolyPeptide enter strategic alliance to scale global peptide supply chain: Our Bureau, Mumbai Friday, December 12, 2025, 14:50 Hrs [IST] Lupin Ma ...
Addex Therapeutics amends its ATM agreement with HC Wainwright & Company: Geneva, Switzerland Friday, December 12, 2025, 14:30 Hrs [IST] Addex Therapeutics, a clinical-stage bioph ...
Germany’s Healy World brings material-science–led digital wellness innovation to India: Our Bureau, Mumbai Friday, December 12, 2025, 14:30 Hrs [IST] Healy World, the Germany- ...
Indoco receives EIR from US FDA for its API manufacturing facility at Patalganga: Our Bureau, Mumbai Friday, December 12, 2025, 14:15 Hrs [IST] Indoco Remedies Limited (Indoco), a ...
Scienture and BlinkRx collaborate to expand patient access to Arbli, an oral suspension formulation of losartan potassium: Commack, New York Friday, December 12, 2025, 14:00 Hrs [ ...
Diakonos Oncology gets grant from Cancer Prevention and Research Institute of Texas to advance DOC1021 in refractory melanoma: Houston Friday, December 12, 2025, 13:00 Hrs [IST] D ...
Ajax Therapeutics receives US FDA’s Orphan Drug Designation for AJ1-11095 to treat patients with myelofibrosis: New York Friday, December 12, 2025, 12:00 Hrs [IST] Ajax Therapeu ...
Roche expands automated mass spectrometry menu with antibiotics drug monitoring CE mark approval offering industry’s broadest in vitro diagnostic menu: Basel Friday, December 12 ...
Pfizer announces Tukysa added to first-line maintenance therapy extends median PFS by over 8 months in patients with HER2+ metastatic breast cancer: New York Friday, December 12, ...